Leading global excellence in procurement and supply

Download Report

Transcript Leading global excellence in procurement and supply

CIPS President – Mission 2013

CIPS Branch Meeting Southampton 14

th

March 2013

Leading global excellence in procurement and supply

Who is Paula Gildert?

1980’s Getting Qualified •Physics Degree •ICI – Chartered Engineer •Open Windows in Engineering •Young Engineer for Britain • Met Steve at Manchester University ‘82 married ‘87 1990’s Getting Going • ICI / Zeneca • Production Manager • BPR Leader • Supply Chain Manager • Fellow RSA • Starbucks Cool Coaching Project Leader • Chair PTA / Chair School Governors • Natalie 90, Naomi 94 2000’s Keeping Going • AstraZeneca •Director Outsourcing •Head UK Purchasing •Global Procurement Transformation Programme Leader • Head R&D Procurement •CIPS Member / Fellow •Natalie to University ‘09 2010’s What next?

•Novartis •Head Development Strategic Sourcing •Chair / President CIPS •CIPS Modernisation Project Sponsor •Numi to University ‘12

Leading global excellence in procurement and supply

What do I want to achieve as President?

• Raise Awareness & Profile of Procurement & Supply Chain as a Profession • Build responsibility for Leadership & Legacy in our Community of Practice

Leading global excellence in procurement and supply

What do I want to achieve as President?

• Promote & Develop our Value proposition – a new winning strategy that goes beyond savings

Leading global excellence in procurement and supply

An Example

Novartis Pharma - Development Gen Meds Cost Reduction Performance

Savings $m 144 96 7% 10% 120 9% 127 Target 9% 2010 2011 2012 2013

Leading global excellence in procurement and supply

What does Value Beyond Savings look like?

Cost Corporate responsibility Continuous Improvement Innovation & Insight Assurance of supply & risk mitigation Quality & Service

Leading global excellence in procurement and supply

DSS – 2012 Executive Summary Dashboard 70-90% of run rate/target Ahead of run rate/target 90 -100% rate/target <70% of run rate/target

Productivity 2012 Sourcing Productivity Savings

Development GenMed Dec 2012 YTD: USD 120m

Measure

Savings Spend* Savings %* LO 2012

YTD Target Status

*based on succeed actuals

Measure

Cost savings Other Development Cost savings Other Novartis Div Cost Avoidance TPC reduction

eROI YTD / Target / LO Status eAuction Spend ( w/Projections), $M

7 | Development Strategic Sourcing| Pharma Dev| Dec 2012 | Sourcing Productivity | Business Use Only

DSS - BSC 2012 Executive Summary 70-90% of run rate/target Ahead of run rate/target 90 -100% rate/target <70% of run rate/target

Measure

Satisfaction* People

Actual Target Status

Internal Processes

Measure

Focus on Core Activities*

Actual Target Status

*portfolio / portfolio enabling: Oct 2012 data * May 2012 DSS pulse check survey results Customer

Measure

Satisfaction*

Actual

* July 2012 DSS customer survey.

Targ et Status

Baseline

Measure

Satisfaction* Quality – actions complete Study Performance Suppliers

YTD Target Status

Baseline Baseline Baseline 8 | Development Strategic Sourcing| Pharma Dev| Dec 2012 | Sourcing Productivity | Business Use Only

Development Productivity 2009-2012

$1bn

in Productivity gains & $900m in Reinvestments

In USD$Mio @ Budget 2012 rates Productivity delivery

Total Reinvestment $900m Key Drivers of Success:

 Embedding productivity in objectives & intro of KPIs  Clinical savings through Design Excellence & use of preferred providers & partners  TRD transformation of clinical supply chain and capacity utilization and process optimization initiatives  Better Development and Productivity Mindset

Actual 2009 Actual 2010 Actual 2011

9 | 2012 Update | Neil Johnston | Jan 2013 | Confidential

Actual 2012

 

Reinvestments to address increased volume needs: Reinvestments into projects above what was expected in budget

Reinvestments into new innovations

Other reinvestments

Financial risk management

Development Productivity 2012 Enabling reinvestment in the pipeline, building capabilities and improving Pharma bottom line 10 | 2012 Update | Neil Johnston | Jan 2013 | Confidential

Leading global excellence in procurement and supply

12

Thought

How does CIPS make this a real possibility?

• Building the Brand on a Global stage • Building Global Standard • Building a Global Network

Leading global excellence in procurement and supply

Strategic Themes FY14 +

Public Good Leading the Global Standard Membership Transformation Knowledge Leadership Global Reach Sustainable growth in Corporate Customers

Leading global excellence in procurement and supply

CIPS – the vital statistics

• Global Community of over 88,000 in 150 countries • Offices in South Africa, Australia, the Middle East, the UK, and setting up in China • Over 130,000 education assessments conducted in 2011 • 8.7 million page views of the CIPS website each year • Our PR coverage exceeds £20 million Advertising Value Equivalent each year • Over 6,000 members a year attend our events including our annual conferences attracting thousands of guests • Purchasing Managers’ Indices, key economic indicators used by the Bank of England and organisations all over the world

Leading global excellence in procurement and supply

CIPS Foundation

Leading global excellence in procurement and supply

CIPS Qualifications Programme

Leading global excellence in procurement and supply

The strategic importance of the Branches

Leading global excellence in procurement and supply

Thank you

Leading global excellence in procurement and supply